Clinical trials: Aromatase Inhibitors
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT06401889
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mayo Clinic
Breast Cancer
Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study
In 2005, the EBCIG demonstrated the efficacy of tamoxifen in improving overall survival in hormone receptor positive breast cancers.
- Trial name
- AIMS (NCT00653718)
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Breast Cancer
Flaxseed, Aromatase Inhibitors and Breast Tumor Characteristics
The proposed study plans to examine the effect of flaxseed consumption, a phytoestrogen rich food, compared to aromatase inhibitors as a complementary approach to treating estrogen receptor positive breast cancer, as well as the…
- Trial name
- FABrC (NCT00612560)
- Testing
- Anastrozole, flaxseed
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors
To see the impact of obesity on the efficacy of adjuvant endocrine therapy with aromatase inhibitors in postmenopausal patients with early breast cancer in terms of: i) Locoregional recurrence ii) Distant metastases iii)…
- Trial name
- NCT01758146
- Testing
- Tamoxifen, Letrozole
- Where
- India
- Volunteers
- 412 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Carcinoma Breast Stage IV
Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer
Steroid Aromatase Inhibitors and Non-Steroid Aromatase Inhibitors in Late Stage Breast Cancer is the recommended scheme in National Comprehensive Cancer Network (NCCN) guideline.
- Trial name
- NCT02161315
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer, Aromatase Inhibitor
Pharmacopuncture for Aromatase Inhibitor Induced Arthralgia (AIA)
This is a pragmatic pilot trial designed to compare and evaluate the efficacy, safety, and cost-effectiveness of pharmacopuncture treatment versus a control group in aromatase inhibitor-induced arthralgia patients with breast…
- Conditions
- Breast Cancer, Aromatase Inhibitor, Aromatase Inhibitor Induced Arthralgia
- Trial name
- P-ATx for AIA (NCT07789717)
- Testing
- pharmacopuncture therapy, Conventional therapy
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Ilsan Cha hospital
Breast Cancer
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
The purpose of this study is to complement Study CBYL719C2301 (SOLAR-1) and obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in…
- Trial name
- EPIK-B5 (NCT05038735)
- Testing
- Alpelisib, Fulvestrant
- Where
- 68 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Relief of Joint Pain
Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms
Significant Aromatase Inhibitor-associated toxicity, affects as many as 50% of patients with breast cancer leading to early discontinuation of this life-saving cancer treatment.
- Trial name
- NCT03069313
- Testing
- Vitamin B12
- Volunteers
- 41 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Anxiety Disorder, Breast Cancer
Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Acupuncture may help relieve muscle and bone pain caused by aromatase inhibitor therapy, such as letrozole, exemestane, and anastrozole.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Fatigue
- Trial name
- NCT00641303
- Testing
- acupuncture therapy
- Where
- 2 sites in United States
- Volunteers
- 51 people
- Sponsor
- University of Maryland, Baltimore
Breast Cancer
Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer
The study is designed to compare the clinical benefit following treatment with aromatase inhibitor in combination with metronomic capecitabine versus aromatase inhibitor alone in women with hormone receptor-positive…
- Trial name
- MECCA (NCT02767661)
- Testing
- Capecitabine, Aromatase Inhibitor
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Sun Yat-sen University
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations.
- Trial name
- Treat ER+ight (NCT02753686)
- Testing
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
- Where
- 25 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer
Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World Study
This study aims to enroll premenopausal patients, with early breast cancer who are non-low-risk and hormone receptor-positive and have undergone prior surgical intervention at the Breast Cancer Center of Sun Yat-sen Memorial…
- Conditions
- Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk, Ovarian Function Suppression Combined With Aromatase Inhibitor or Tamoxifen or Torimefen
- Trial name
- NCT05801705
- Testing
- Aromatase inhibitor, ovarian function suppression (Oophorectomy, Ovarian irradiation, Gonadotropin-releasing hormone agonist), Tamoxifen
- Where
- China
- Volunteers
- 700 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Breast Cancer
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
This study is being done to look at the role of continuing palbociclib treatment in combination with another type of hormonal therapy (fulvestrant) after disease progression of palbociclib in combination with an aromatase…
- Trial name
- NCT02738866
- Testing
- Palbociclib, Fulvestrant
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients
To compare safety of adjuvant OFS combined with anastrozole versus OFS combined with exemestane in Chinese premenopausal hormonal receptor(HR) positive breast cancer patients.
- Trial name
- SEAT (NCT02440230)
- Testing
- OFS + Anastrozole, OFS + Exemestane
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Osteoporosis Secondary, Breast Cancer Females
Vitamin k, D-chiro Inositol and α-lactalbumin in Bone Homeostasis
In women with breast cancer undergoing adjuvant hormone therapy, the marked tissue hypoestrogenism induced by therapy with aromatase inhibitors and/or tamoxifen ± GnRH analogues causes a significant acceleration in bone mass…
- Trial name
- Synostea (NCT07256769)
- Testing
- Group 1: calcium carbonate/cholecalciferol, Group 2: Synostea® (calcium carbonate/cholecalciferol/vitamin K/α-lactalbumin/ d-chiro-inositol)
- Where
- 2 sites in Italy
- Volunteers
- 134 people
- Sponsor
- Regina Elena Cancer Institute
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
This phase II trial studies the impact of a presurgical endocrine therapy, consisting of goserelin with letrozole or anastrozole on the treatment of premenopausal patients with stage II-III estrogen receptor-positive (ER+) and…
- Conditions
- Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT01368263
- Testing
- goserelin acetate, letrozole, anastrozole
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
The primary objective of this study is to determine if estrogen receptor-targeted therapy with fulvestrant used in combination with Everolimus is an effective and safe therapy for women with hormone receptor positive metastatic…
- Trial name
- BRE-43 (NCT00570921)
- Testing
- Everolimus, Fulvestrant
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Mara Chambers
Breast Cancer
BREADS: Breast Adjuvant Diet Study
This is a randomized controlled trial of a 6-month extreme carbohydrate restricted diet (20 grams total carbs/day) via phone counseling with dietitian plus aromatase inhibitor therapy vs.
- Trial name
- NCT04189263
- Testing
- Carbohydrate restricted dietary intervention, standard of care aromatase inhibitors
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Farin Amersi
Breast Cancer, Postmenopausal
Effect of Aromatase Inhibitors on Bones and Genes
The primary objective of this 2-year pilot project is to test the hypothesis that skeletal response to aromatase inhibitors is determined by polymorphisms of the CYP19 gene.
- Trial name
- NCT00603967
- Testing
- Dual x-ray absorptiometry (DXA), Blood draw, Questionnaire
- Where
- United States
- Volunteers
- 151 people
- Sponsor
- Washington University School of Medicine
Silver Russell Syndrome, Prader-Willi Syndrome
Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome
There is currently no drug with pediatric marketing authorization capable of limiting the advance in bone maturation of children with aggressive adrenarche.
- Trial name
- ANASILPRA (NCT01520467)
- Testing
- Anastrozole
- Where
- France
- Volunteers
- 27 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris